Chemotherapy and Endocrine Therapy Regimens

The most frequently used regimens are shown in this chapter (Tables 4-12). The efficacy of the adjuvant treatment depends largely on the dosage applied and on the frequency of therapy courses. Therefore reduction of the dosage and lengthening of the cycles should be avoided.

The cytostatic regimens are listed first. Note that CMF is still the most frequently used basic regimen (Tables 4, 5); in cases with higher degrees of malignancy (even in N0 stages) and in cases with positive nodes or HER/neu overexpression, however, anthracyclin-containing therapy regimens (Tables 6-9) are definitely preferred. In cases with

Table 2. Classification according to risk factors for patients with node-negative breast cancer (modified according to Goldhirsch et al. 2003)

Risk category

Endocrine responsive

Endocrine non-

responsive

Minimal

ER and/or PR positive and all of the following: pT < 2 cm, grade 1, age > 35 years

Not applicable

Average

ER and/or PR positive and one of the following: pT > 2 cm, grade 2-3, age < 35 years

ER and PR negative

Table 3. Adjuvant systemic treatment for patients with operable breast cancer (modified according to Goldhirsch et al. 2003)

Risk category

Endocrine responsive

Endocrine nonresponsive

0 0

Post a comment